01 · The Goal

Restore the body’s own ability to make insulin

The goal is to restore the body’s own insulin production — ending dependence on lifelong injections in diabetes. Behind the biology is a human being who would feel the difference in their daily life — that is the whole point.

02 · Why It Matters

The pancreas makes both the insulin that controls blood sugar and the enzymes that digest food. When its insulin-producing cells are lost, diabetes follows and means lifelong injections; when its digestive function fails, nutrition suffers. Restoring the body’s own insulin and digestive capacity would change diabetes and pancreatic disease at the root. For someone with diabetes, restoring the body’s own insulin is the difference between managing a disease and being free of it.

03 · What We’re Trying to Achieve

We are building the capability to restore insulin production: replacing the insulin-making cells, protecting them from the immune system, and regenerating them in the body. The aim is a clear path from what already works in the clinic today to the regenerative science advancing toward tomorrow — honestly staged at every step.

04 · How It Works

How it works

Stem-cell-derived islets Demonstrated in research

Insulin-producing cells made from stem cells have restored insulin production in early human trials.

Protecting new cells Frontier

Shielding transplanted islets from immune attack — without lifelong immune suppression — is a key frontier.

Regenerating islets in place Frontier

Coaxing the pancreas to regrow its own insulin cells is early-stage laboratory science.

Pairing repair with rehabilitation Clinical

Combining tissue or cell repair with intensive, targeted rehabilitation drives the fullest functional recovery — established in practice.

05 · Who’s Building It

Cited as evidence the capability is real — not as partners or endorsers.

Government & programs

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, NIH) · NIH diabetes programs. These public programs fund the foundational research that shows the capability is real.

Universities & institutes

Academic diabetes, islet-biology, and pancreas-regeneration research centers. Academic laboratories carry that science from discovery toward the clinic.

Enabling science base

beta-cell & islet biology · stem-cell-derived islets · exocrine biology · immune tolerance. — the established disciplines this capability is built upon.

06 · Technologies

The technologies: stem-cell-derived insulin-producing cells, islet replacement and protection, exocrine-restoration approaches, and immune-tolerance therapies that protect new cells.

07 · Breakthroughs

Stem-cell islets Demonstrated

Lab-made islets restore insulin in early trials.

Immune protection Frontier

Protecting new cells without suppression is early-stage.

In-place regeneration Frontier

Regrowing islets in the body is early-stage.

Clinical translation underway Clinical trials

Several restorative approaches have moved from the lab into human trials — the bridge from demonstrated biology to everyday care.

08 · Remaining Challenges

The honest challenges: making insulin-producing cells is demonstrated; protecting them durably from the immune system and scaling the approach are the central frontiers. Getting new cells and tissue to survive, connect, and function durably in a living person — not just in a dish or an animal — is the central work, and it is exactly where the most careful, best-funded research is now aimed. We show where each piece stands, so the promise is never mistaken for the proof.

09 · Mature Capability

The future, fully built

A person with diabetes has their own insulin production restored — insulin-making cells replaced and protected — so daily injections give way to a body that regulates itself. — and the honest staging on this page shows just how much of that future is already real, and how much is still being built.

Honest boundary: each item is tagged for where it stands — demonstrated, clinical, or frontier. The science is real, funded, and accelerating. AI supports human clinicians; it never replaces them.
10 · Evidence Vault

The proof, for this capability

Cited as evidence the capability is real, not as partners or endorsers.

Stem-cell islets

Restore insulin in early human trials. Stage: Demonstrated.

Immune protection

Durable protection without suppression is early-stage. Stage: Frontier.

In-place regeneration

Regrowing islets is early-stage. Stage: Frontier.

Honest framing

Real organizations are cited as evidence the capability is real — not as partners or endorsers. Stem-cell islets are demonstrated in early trials; durable, suppression-free protection in people is frontier.

Where it stands

Each line above is tagged for its stage — demonstrated, clinical, or frontier — so the page shows exactly how far the real science has come, and how far is left.

Help build this future

Every signature grows the movement to make insulin-production restoration real — and free at the point of need.

Paid for by Michael Floyd for President.

Scroll to Top